Edwards Lifesciences (EW) Reports In-Line Q3 EPS

Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.68, in-line with the analyst estimate of $0.68. Revenue for the quarter came in at $739.4 million versus the consensus estimate of $749.14 million.

GUIDANCE:

Edwards Lifesciences sees Q4 2016 EPS of $0.67-$0.77, versus the consensus of $0.74. Edwards Lifesciences sees Q4 2016 revenue of $750-790 million, versus the consensus of $801.14 million.

Edwards Lifesciences sees FY2016 EPS of $2.82-$2.92, versus the consensus of $2.88. Edwards Lifesciences sees FY2016 revenue of $2.7-3.0 billion, versus the consensus of $2.94 billion.

"We are pleased to report strong third quarter underlying sales growth of 18 percent, which was consistent with our increased expectations," said Michael A. Mussallem, chairman and CEO. "2016 has been a remarkable year for our company. This performance reflects continued strong global adoption of our Edwards SAPIEN 3 valve platform, which remains on track to generate over $300 million more in sales than we originally expected for the year. Consistent with our strategy, we are aggressively investing to bring break-through therapies to an even broader group of patients around the world."

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Morgan Stanley says PagerDuty stock is 'too cheap to ignore'; Shares gain after earnings
• Samsara Inc (IOT) Tops Q3 EPS by 3c; offers guidance
• Elastic N.V. (ESTC) Tops Q2 EPS by 13c; offers guidance